Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Purple Biotech ( (PPBT) ) is now available.
On July 23, 2025, Purple Biotech Ltd. announced significant progress in its clinical programs during the first half of the year. The company highlighted advancements in its CM24, NT219, and CAPTN-3 platforms, with promising results from Phase 2 studies and strategic milestones achieved. The CM24 study showed strong efficacy signals in pancreatic cancer patients, while the CAPTN-3 platform demonstrated potential in enhancing safety and potency. The company plans to advance its clinical trials and expects further developments in 2026, maintaining a financial runway into mid-2026.
The most recent analyst rating on (PPBT) stock is a Buy with a $160.00 price target. To see the full list of analyst forecasts on Purple Biotech stock, see the PPBT Stock Forecast page.
Spark’s Take on PPBT Stock
According to Spark, TipRanks’ AI Analyst, PPBT is a Underperform.
Purple Biotech’s overall stock score reflects significant financial challenges and unattractive valuation metrics. The absence of revenue and ongoing losses weigh heavily on financial performance. Technical indicators are mixed, with some potential downside risks. The lack of profitability and dividends further contribute to a low valuation score.
To see Spark’s full report on PPBT stock, click here.
More about Purple Biotech
Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. Their oncology pipeline includes CM24, NT219, and CAPTN-3, targeting various cancer indications by leveraging novel pathways and immune system activation. The company is headquartered in Rehovot, Israel.
Average Trading Volume: 110,094
Technical Sentiment Signal: Buy
Current Market Cap: $7.82M
Learn more about PPBT stock on TipRanks’ Stock Analysis page.